Genetic changes in ovarian cancer - PubMed (original) (raw)
Review
Genetic changes in ovarian cancer
T Pejovic. Ann Med. 1995 Feb.
Free article
Abstract
The development of cancer is a multistep process involving accumulation of genetic changes which progressively transform normal cells to neoplastic cells. During the last few years, our understanding and knowledge of the genetic changes involved in ovarian carcinogenesis have increased dramatically. In this review I will focus on karyotypic abnormalities in ovarian cancer and will also refer to molecular studies involving alterations in oncogenes and tumour suppressor genes in ovarian tumorigenesis. Cytogenetic analyses have identified two distinct subgroups. Simple karyotypic changes, trisomy 12 being the most common aberration in this group, are recurrently found in well differentiated ovarian carcinomas. Complex karyotypic abnormalities, including predominantly chromosome losses, deletions and unbalanced translocations, are found in moderately and poorly differentiated carcinomas. The bands and regions most commonly involved in structural rearrangements have been, in decreasing order of frequency, 19p13, 1p36, 1q21, 1q23-25, 3p11-13, 6q21, 19q13, 11p13-15, 11q13, 11q23, 12q24, 12p11-13, and 7p13-22. The finding of identical karyotypic and other genetic changes in tumour samples taken from different sites, such as tumours from both ovaries and omental metastases, indicate that ovarian cancer is of unicentric origin with subsequent metastatic spread giving rise to multiple implants. Molecular genetic changes important in ovarian cancer involve both classes of tumor-associated genes: RAS activation is generally not observed in ovarian cancer. Alterations of MYC1, ERBB2, AKT2, TP53 has been described in some ovarian carcinomas. The temporal relationship of these mutations, i.e. early or late events in ovarian carcinogenesis, remains to be determined.
Similar articles
- Chromosome aberrations in 35 primary ovarian carcinomas.
Pejovic T, Heim S, Mandahl N, Baldetorp B, Elmfors B, Flodérus UM, Furgyik S, Helm G, Himmelmann A, Willén H, et al. Pejovic T, et al. Genes Chromosomes Cancer. 1992 Jan;4(1):58-68. doi: 10.1002/gcc.2870040108. Genes Chromosomes Cancer. 1992. PMID: 1377010 - Oncogenesis in ovarian cancer.
Børresen AL. Børresen AL. Acta Obstet Gynecol Scand Suppl. 1992;155:25-30. doi: 10.1111/j.1600-0412.1992.tb00004.x. Acta Obstet Gynecol Scand Suppl. 1992. PMID: 1502889 Review. - Recurrent cytogenetic aberrations in human ovarian carcinomas.
Kiechle-Schwarz M, Bauknecht T, Schmidt J, Walz L, Pfleiderer A. Kiechle-Schwarz M, et al. Cancer Detect Prev. 1995;19(3):234-43. Cancer Detect Prev. 1995. PMID: 7750111 - Genetic aspects of ovarian cancer.
Karlan BY, Krakow D. Karlan BY, et al. Curr Opin Obstet Gynecol. 1994 Feb;6(1):105-10. doi: 10.1097/00001703-199402000-00017. Curr Opin Obstet Gynecol. 1994. PMID: 8180345 Review. - Cytogenetics and molecular genetics of human solid tumours.
Sahlin P, Stenman G. Sahlin P, et al. Scand J Plast Reconstr Surg Hand Surg. 1995 Jun;29(2):101-10. doi: 10.3109/02844319509034326. Scand J Plast Reconstr Surg Hand Surg. 1995. PMID: 7569807 Review.
Cited by
- EphA2 overexpression promotes ovarian cancer growth.
Lu C, Shahzad MM, Wang H, Landen CN, Kim SW, Allen J, Nick AM, Jennings N, Kinch MS, Bar-Eli M, Sood AK. Lu C, et al. Cancer Biol Ther. 2008 Jul;7(7):1098-103. doi: 10.4161/cbt.7.7.6168. Epub 2008 Apr 19. Cancer Biol Ther. 2008. PMID: 18443431 Free PMC article. - Ovarian cancer biomarkers: a focus on genomic and proteomic findings.
Tinelli A, Vergara D, Martignago R, Leo G, Malvasi A, Tinelli R, Marsigliante S, Maffia M, Lorusso V. Tinelli A, et al. Curr Genomics. 2007 Aug;8(5):335-42. doi: 10.2174/138920207782446142. Curr Genomics. 2007. PMID: 19384429 Free PMC article. - Differential regulation of EphA2 in normal and malignant cells.
Walker-Daniels J, Hess AR, Hendrix MJ, Kinch MS. Walker-Daniels J, et al. Am J Pathol. 2003 Apr;162(4):1037-42. doi: 10.1016/S0002-9440(10)63899-0. Am J Pathol. 2003. PMID: 12651595 Free PMC article. Review. No abstract available. - Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.
Kurose K, Zhou XP, Araki T, Cannistra SA, Maher ER, Eng C. Kurose K, et al. Am J Pathol. 2001 Jun;158(6):2097-106. doi: 10.1016/S0002-9440(10)64681-0. Am J Pathol. 2001. PMID: 11395387 Free PMC article. - Aberrant expression of EphA3 in gastric carcinoma: correlation with tumor angiogenesis and survival.
Xi HQ, Wu XS, Wei B, Chen L. Xi HQ, et al. J Gastroenterol. 2012 Jul;47(7):785-94. doi: 10.1007/s00535-012-0549-4. Epub 2012 Feb 17. J Gastroenterol. 2012. PMID: 22350700
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous